What kind of uptake can Gilead expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) injection ...

Gilead Sciences (NasdaqGS:GILD) recently entered an exclusive agreement with Kymera Therapeutics to advance a molecular glue degrader program targeting CDK2, enhancing its oncology pipeline.

Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Teen idol Bobby Sherman dies at 81 Sherman had four Top 10 hits on the Billboard Hot 100 chart: “Little Woman,” “Julie, Do Ya Love Me,” “Easy Come, Easy Go,” and “La La La (If I Had You).” ...

Kymera’s programme focuses on removing CDK2 from cells compared to other therapies that target the protein’s inhibition.

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

Lenacapavir, created by Foster City-based Gilead Sciences, has been in use for several years as a treatment for HIV/AIDS ...

Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV ...

Eazy-E was one of the first major music performers to announce he has the disease. Health experts and AIDS activists in 1995 said his declaration forces the public face of AIDS into another community, ...

In a bold step toward global health justice, Ugandan biotech company DEI BioPharma has announced it will begin manufacturing ...